Pulse Biosciences (NASDAQ:PLSE) CTO Darrin Uecker Sells 25,000 Shares

Key Points

• Pulse Biosciences CTO Darrin Uecker sold 25,000 shares of stock for approximately $394,250, reducing his ownership of the company by 16.91%.
• The company's stock price rose 8.4% to $15.74 on Monday, with a market cap of over $1.06 billion.
• Analysts have set a price target of $22.00 for Pulse Biosciences, with the stock currently holding an average rating of "Buy".

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) CTO Darrin Uecker sold 25,000 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $15.77, for a total value of $394,250.00. Following the sale, the chief technology officer owned 122,872 shares in the company, valued at $1,937,691.44. The trade was a 16.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Darrin Uecker also recently made the following trade(s):

• On Wednesday, September 17th, Darrin Uecker sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $16.21, for a total value of $324,200.00.
• On Thursday, September 11th, Darrin Uecker sold 25,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $14.78, for a total value of $369,500.00.

Pulse Biosciences Trading Down 4.9%

NASDAQ:PLSE traded down $0.91 during midday trading on Friday, hitting $17.61. 523,812 shares of the company traded hands, compared to its average volume of 204,930. The firm's fifty day moving average is $15.57 and its 200-day moving average is $16.15. Pulse Biosciences, Inc has a 12-month low of $13.77 and a 12-month high of $25.00. The firm has a market capitalization of $1.19 billion, a P/E ratio of -16.77 and a beta of 1.68.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Institutional Investors Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its stake in Pulse Biosciences by 0.4% in the fourth quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock valued at $13,727,000 after buying an additional 2,884 shares during the last quarter. Geode Capital Management LLC raised its stake in Pulse Biosciences by 7.2% in the second quarter. Geode Capital Management LLC now owns 499,464 shares of the company's stock valued at $7,538,000 after buying an additional 33,744 shares during the last quarter. Westside Investment Management Inc. raised its stake in Pulse Biosciences by 10.5% in the second quarter. Westside Investment Management Inc. now owns 64,290 shares of the company's stock valued at $970,000 after buying an additional 6,135 shares during the last quarter. Nuveen LLC purchased a new stake in Pulse Biosciences in the first quarter valued at about $915,000. Finally, Panoramic Capital LLC raised its stake in Pulse Biosciences by 8.5% in the first quarter. Panoramic Capital LLC now owns 52,723 shares of the company's stock valued at $848,000 after buying an additional 4,152 shares during the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Oppenheimer initiated coverage on Pulse Biosciences in a research report on Monday, July 7th. They issued an "outperform" rating and a $22.00 price objective on the stock. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $22.00.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.